Gennex Laboratories Ltd


BSE: 531739 | NSE: NA | ISIN: INE509C01026 
Market Cap: [Rs.Cr.] 11 | Face Value: [Rs.] 1
Industry: Pharmaceuticals - Indian - Bulk Drugs

 Discuss this stock

Management Discussions

MANAGEMENT'S DISCUSSION AND ANALYSIS REPORT

Management's Discussion and Analysis Report on the Business of the Company asapplicable and to the extent relevant is given below:

Overview & Operations of the Company

Gennex Laboratories Limited is in the business of Manufacturing of Bulk Drugs,Intermediates and Biotech Products. The Company is having a professionally managed team atevery stage of its operations.

Strengths

Multipurpose and Multi product production facilities having ISO 9001:2008 and TUVCertificate 44100 124194-E3. The Company is in the process of obtaining ISO 14001 andOSHAS 18000 Certification by 2013-14.

- The Management depth and ability to manage client relationships.

- Enhanced presence in the international market.

Opportunities & Threats

Large number of Pharmaceutical companies losing their drug patents, thereby increasingthe scope of outsourcing to countries that offer a low cost manufacturing base.

The Pharma sector is expected to witness further consolidation by way of mergers andacquisitions this augurs for growth of the Industry. This would result in better pricerealization and growth.

The Indian Pharma Industry will have to meet the following challenges:

i. Multinational Companies are setting up large plants in India.

ii. Competition in the global market that offer low manufacturing base.

iii. Uncertainties on account of global socio economic environment.

Outlook for the Company

Your Company is on the verge of completion of the expansion plans undertaken. YourCompany has planned its business strategy taking the ground realities into account. TheCompany has introduced new products which are very competitive and beneficial to theCompany.

Risks and concerns

Any Government policy intervention or any change in the Pharma sector benefits andunforeseen adverse market conditions are issues of concern and may put pressure on theperformance of the Company.

Internal control system and their adequacy

The Company has Internal Control System which is adequate and commensurate with thesize of the Company.

Cautionary Statement

Statement in this "Management Analysis Report" be considered to be forwardlooking statements with in the meaning of applicable securities laws or regulations.Actual result could differ materially from those expressed or implied. Important factorsthat could make a difference to the Company's operations include global and Indian demandsupply conditions, increased installed capacity, price bulk drugs and its availability,cyclical demands and pricing in the Company's market, changes in Government regulations,tax regimes, besides other factors such as litigations and labour negotiations.

   

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Lupin 42,831.10 22.71 8.84 15.10 29.4 33.5 0.21
Divi's Lab. 17,600.00 22.55 6.89 14.99 25.9 32.9 0.02
Jubilant Life 2,724.03 11.92 1.46 15.32 4.2 7.0 1.52
Shilpa Medicare 1,581.85 22.35 4.78 9.81 14.9 14.9 0.25
Vinati Organics 1,319.13 16.49 5.47 5.75 32.1 27.2 0.96
Marksans Pharma 876.56 10.02 9.10 4.97 41.9 19.5 0.00
Suven Life Scie. 876.00 7.27 5.67 6.69 21.9 18.5 0.76
Hikal 812.71 10.03 2.37 8.61 -2.5 5.0 1.57
Dishman Pharma. 713.79 12.56 0.99 5.90 9.1 11.6 0.72
Sequent Scien. 660.26 0.00 6.27 0.00 0.0 0.0 2.06
Granules India 561.15 8.49 2.07 5.09 11.7 13.3 0.76
Nectar Lifesci. 517.01 7.48 0.60 4.00 10.4 12.8 1.16
Shasun Pharma. 496.67 19.63 1.73 9.51 9.6 8.3 1.17
Elder Pharma 473.65 61.66 0.61 5.93 10.2 11.5 1.38
Aarti Drugs 390.67 7.38 1.88 3.80 23.6 19.9 1.48

Futures & Options Quote

 
Expiry Date
NA
Instrument: NA
Expiry Date: NA
Strike Price: NA
Open Price: NA
Average Price: NA
No. of Contracts Traded: NA
Open Interest: NA
Underlying: NA
Option Type: NA
Market Lot: NA
Previous Close: NA
Day’s High | Low: NA | NA
Turnover (Cr.): NA
Open Int. Change: NA | NA
View detailed F& O quotes >>

Key Information

Key Executives:

U C Bhandari , Director  

Y Ravinder Reddy , Director  

Arihant Baid , Managing Director &Addtnl Dir.  

Tiruvarur Muralidharan Gopalakrishnan , Addi.Direct. & Whole Time Dire  


Company Head Office / Quarters:
Survey No 133 Bollaram,
Jinnaram Mandal,
Medak,
Andhra Pradesh-502325
Phone : 91-8452-279516/279406
Fax : 91-8452-279516
E-mail :
Web : http://
Registrars:
AMI Computers (I) Ltd
60A & 60B
Chowringhee Road
2nd Floor
Kolkata - 700 0207A Betala Road
1st Floor

Kolkata - 700 026

Fund Holding

 
Scheme Name No. of Shares
No data found

Calendar

Apr-2014
M T W T F S S
14 15 16 17 18 19 20
IPO
listNo IPO today
Economic Events
list No economic event today
Results
list No result today